Harbour BioMed Reclaims Rights to HBM7008 as Cullinan Therapeutics Cancels Licensing Deal
Harbour BioMed (HBM), a biopharmaceutical company with operations in the Netherlands, the United States, and...
Wondfo Biotech and University of Science, Malaysia Deepen Ties with Formal Partnership
Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482), a biotechnology firm based in China, has formalized...
WestGene Biopharma’s EB Virus-Targeting mRNA Vaccine WGc-043 Clears for Clinical Trials in China
WestGene Biopharma Co., Ltd., a biotechnology company based in Chengdu, has received approval from the...
Hansoh Pharmaceutical Secures Rights to Lupeng’s BTK Inhibitor LP-168 in Licensing Deal
Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692), a leading pharmaceutical company based in China, has...
Zelgen Biopharmaceuticals’ ZG006 Earns Orphan Drug Designation from FDA for Small-Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...
Novo Nordisk Reports 25% YOY Sales Growth in H1 and Q2 2024, Led by GLP-1 Drugs
Novo Nordisk (NYSE: NVO), a Danish pharmaceutical giant specializing in diabetes care, has reported its...
Pfizer, Astellas, and University of California Sue Qilu Pharma Over Xtandi Patent Infringement
Pfizer Inc. (NYSE: PFE), through its subsidiary Medivation, and co-development partner Astellas Pharma Inc. (TYO:...
WuXi Biologics Partners with Medigene for TCR TCE Development in Refractory Tumors
WuXi Biologics (HKG: 2269), a leading Contract Research, Development and Manufacturing Organization (CRDMO) in China,...
Eli Lilly & Co. Resolves Manufacturing Constraints, Reports 37% YOY Sales Growth in Q2 2024
Eli Lilly & Co. (NYSE: LLY), a prominent pharmaceutical company based in the U.S., has...
AI-Driven Drug Firms Recursion and Exscientia to Merge in a Deal Valued at Approximately USD 850 Million
Recursion (NASDAQ: RXRX), a U.S.-based clinical-stage TechBio company, and Exscientia plc (NASDAQ: EXAI), a U.K.-headquartered...
Viatris Inc. Reports 2% Operational Growth in Q2’24, Driven by Generics and Brands
Viatris Inc. has announced its financial results for the second quarter of 2024, highlighting approximately...
Insilico Medicine’s ISM6331 Earns FDA Orphan Drug Designation for Mesothelioma Treatment
Insilico Medicine, a China-based biotechnology company at the forefront of generative artificial intelligence (AI), has...
BeiGene’s Q2 2024 Revenues Surge 56% YOY, Highlighted by Strong U.S. Market Performance
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has reported its financial results for the second...
Betta Pharmaceuticals Reports Strong H1 2024 Revenue Growth and Advances in Drug Development
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has reported its financial results...
NHSA Preliminary Review Identifies Potential NRDL Additions, Including Novel Therapies and ADCs
The National Healthcare Security Administration (NHSA) has released a preliminary list of drugs that have...
Shanghai Pharmaceuticals’ SH-INNO Incubator to Drive Biopharmaceutical Innovation and Collaboration
Shanghai Pharmaceuticals (SPH;HKG: 2607; SHA: 601607) has launched the “SH-INNO incubator,” a collaborative initiative with...
Hygeia Healthcare Holdings Acquires Chang An Hospital in Deal Valued at RMB 1.66 Billion
Hygeia Healthcare Holdings Co., Ltd, a Shanghai-based medical investment and healthcare group, has announced the...
Changshan Biochemical Gets Marketing Nod for Enoxaparin in Kyrgyzstan for Venous Thromboembolic Diseases
Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255), a Chinese pharmaceutical company, has announced...
Haisco Pharmaceutical’s PDE4B Inhibitor HSK44459 Gets NMPA Green Light for Interstitial Lung Disease Clinical Trial
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a Chinese pharmaceutical company, has announced that it...
Vazyme Biotech Secures NMPA Nod for Two RSV Antigen Detection Kits
Vazyme Biotech Co., Ltd (SHA: 688105), a biotechnology company based in China, has announced that...